TCB-2

Source: Wikipedia, the free encyclopedia.

TCB-2
Clinical data
Routes of
administration
Oral
ATC code
  • none
Legal status
Legal status
  • In General Unscheduled
Identifiers
  • [(7R)-3-Bromo-2,5-dimethoxy-bicyclo[4.2.0]octa-1,3,5-trien-7-yl]methanamine
JSmol)
SMILES
  • COc1c(Br)cc(OC)c2c1CC2CN
  • InChI=1S/C11H14BrNO2/c1-14-9-4-8(12)11(15-2)7-3-6(5-13)10(7)9/h4,6H,3,5,13H2,1-2H3/t6-/m0/s1
  • Key:MPBCKKVERDTCEL-LURJTMIESA-N
  (verify)

TCB-2 is a

derivative of the phenethylamine 2C-B, also a hallucinogen, and acts as a potent agonist for the 5-HT2A and 5-HT2C receptors with a Ki
of 0.26 nM at the human 5-HT2A receptor.

In drug-substitution experiments in rats, TCB-2 was found to be of similar potency to both LSD and Bromo-DragonFLY, ranking it among the most potent phenethylamine hallucinogens yet discovered.[1] This high potency and selectivity has made TCB-2 useful for distinguishing 5-HT2A receptor-mediated responses from those produced by other similar receptors.[2]

TCB-2 has similar but not identical effects in animals to related phenethylamine hallucinogens such as

cocaine addiction and neuropathic pain.[3][4][5][6] It has also been found to produce rapid antidepressant-, anti-anhedonic-, and anxiolytic-like effects in animals.[7]

See also

References

This page is based on the copyrighted Wikipedia article: TCB-2. Articles is available under the CC BY-SA 3.0 license; additional terms may apply.Privacy Policy